AR105327A1 - Derivados de imidazol - Google Patents

Derivados de imidazol

Info

Publication number
AR105327A1
AR105327A1 ARP160102101A ARP160102101A AR105327A1 AR 105327 A1 AR105327 A1 AR 105327A1 AR P160102101 A ARP160102101 A AR P160102101A AR P160102101 A ARP160102101 A AR P160102101A AR 105327 A1 AR105327 A1 AR 105327A1
Authority
AR
Argentina
Prior art keywords
methyl
cyclopropyl
cyano
isopropyl
ethyl
Prior art date
Application number
ARP160102101A
Other languages
English (en)
Inventor
Wichmann Juergen
Hoener Marius
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR105327A1 publication Critical patent/AR105327A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente está relacionada con compuestos de fórmula (1) en el que R¹ es CH₃; R¹ es metilo, etilo, CF₃, CH₂OH, ciclopropilo o ciano, o R¹ y R¹ pueden formar juntos un anillo 1,1-dioxo-tetrahidro-tiofen-3-ilo; R² es hidrógeno, metilo, etilo, isopropilo, terc-butilo, ciclopropilo, hidroximetilo, o 2-propil-2-ol; R³ es Cl, F, CF₃, metilo, metoxi, isopropilo, ciano o ciclopropilo; R⁴ es hidrógeno, metilo, F o Cl; o una sal farmacéuticamente aceptable o sal de adición ácida, una mezcla racémica, o su correspondiente enantiómero y/o isómero óptico y/o estereoisómero de los mismos. Los compuestos de fórmula (1) pueden utilizarse en el tratamiento de trastornos psiquiátricos como esquizofrenia, trastorno bipolar, trastorno obsesivo compulsivo o trastorno del espectro autista.
ARP160102101A 2015-07-14 2016-07-12 Derivados de imidazol AR105327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15176652 2015-07-14

Publications (1)

Publication Number Publication Date
AR105327A1 true AR105327A1 (es) 2017-09-27

Family

ID=53757994

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102101A AR105327A1 (es) 2015-07-14 2016-07-12 Derivados de imidazol

Country Status (8)

Country Link
US (1) US10092546B2 (es)
EP (1) EP3322699B1 (es)
JP (1) JP6846363B2 (es)
CN (1) CN107709311B (es)
AR (1) AR105327A1 (es)
HK (1) HK1250028A1 (es)
TW (1) TW201713639A (es)
WO (1) WO2017009274A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6518789B2 (ja) 2015-04-23 2019-05-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 精神障害の処置において使用するためのテトラゾール誘導体
EP3322699B1 (en) * 2015-07-14 2019-05-15 H. Hoffnabb-La Roche Ag 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors
WO2017133990A1 (en) * 2016-02-02 2017-08-10 F. Hoffmann-La Roche Ag Pyrazol-pyridine derivatives as eaat3 inhibitors
JP7068277B2 (ja) 2016-10-14 2022-05-16 エフ．ホフマン－ラ ロシュ アーゲー Ｅａａｔ３阻害剤としてのイミダゾール化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
CA2658362A1 (en) * 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
JP2011530483A (ja) * 2008-08-12 2011-12-22 武田薬品工業株式会社 アミド化合物
WO2010033168A2 (en) * 2008-09-18 2010-03-25 Renovis, Inc. Amide compounds, compositions and uses thereof
WO2010051188A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
WO2014078377A1 (en) * 2012-11-14 2014-05-22 Agenebio, Inc. Methods and compositions for treating schizophrenia
EP3322699B1 (en) * 2015-07-14 2019-05-15 H. Hoffnabb-La Roche Ag 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors

Also Published As

Publication number Publication date
EP3322699A1 (en) 2018-05-23
HK1250028A1 (zh) 2018-11-23
EP3322699B1 (en) 2019-05-15
JP2018520135A (ja) 2018-07-26
US20180125823A1 (en) 2018-05-10
CN107709311A (zh) 2018-02-16
TW201713639A (zh) 2017-04-16
WO2017009274A1 (en) 2017-01-19
US10092546B2 (en) 2018-10-09
JP6846363B2 (ja) 2021-03-24
CN107709311B (zh) 2020-09-25

Similar Documents

Publication Publication Date Title
AR104331A1 (es) Derivados de tetrazol
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2018000036A1 (es) Derivados etinilo
AR105662A1 (es) Derivados de piridina y de pirimidina como inhibidores del eaat3
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR104863A1 (es) Derivados imidazol
CO6531444A2 (es) Métodos sintéticos para compuestos espiro-oxoindol
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
AR105327A1 (es) Derivados de imidazol
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
AR099047A1 (es) Derivados etinilo
AR094346A1 (es) Derivados de azaindol como inhibidores de las proteína quinasas
AR103412A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
AR098522A1 (es) Compuesto de triazolo-piridina
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
CL2019000462A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional solicitud 201603258)
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
AR097721A1 (es) Derivados de etinilo
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
AR107490A1 (es) Derivados de pirazol-piridina como inhibidores de eaat3
AR106475A1 (es) Derivados de piridina o de pirimidina
AR101136A1 (es) Proceso para la preparación de ácidos 3-hidroxipicolínicos
CO2018013824A2 (es) Derivados de etinilo

Legal Events

Date Code Title Description
FB Suspension of granting procedure